ProCE Banner Activity

Elotuzumab/Lenalidomide/Dexamethasone Maintenance After ASCT in Patients With MM: Preliminary Results From a Phase II Study

Slideset Download
Conference Coverage
Use of elotuzumab/lenalidomide/dexamethasone maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma improved quality of response in 36% of patients in this preliminary analysis.

Released: December 18, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology